To hear about similar clinical trials, please enter your email below
Trial Title:
A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure
NCT ID:
NCT05489926
Condition:
Epithelial Ovarian Cancer
Conditions: Official terms:
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Pamiparib
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Active, not recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Pamiparib
Description:
Pamiparib, 60mg PO BID
Arm group label:
Pamiparib
Summary:
The PamiAP will be a Phase II, single-arm, open label study to explore the efficacy and
safety of Pamiparib treatment in patients with Epithelial Ovarian Cancer(EOC) who have
had exposure to prior a PARP (poly(ADP-ribose)-polymerase) inhibitor
Detailed description:
The landscape for treatment of Epithelial Ovarian Cancer(EOC) is rapidly changing. With
the release of data from numerous studies exploring the role of PARP
(poly(ADP-ribose)-polymerase) inhibitor as maintenance and treatment, approval has
expanded significantly in recent years. However, with the widespread exposure of PARP
inhibitor in the patients, whether another PARP inhibitor can be reused in patients with
PARP inhibitor resistance or disease progression. We have no data regarding the efficacy
or safety of a PARP inhibitor retreatment in patients who have had exposure to prior a
PARP inhibitor.
The objective of this study was to evaluate the efficacy and safety of Pamiparib in
patients with EOC who had previously been treated with PARP inhibitor, and to explore the
characteristics of patients who responded to PARP inhibitor again.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. Voluntary participation and signature of informed consent;
2. Age ≥18;
3. Histologically diagnosed relapsed non-mucinous epithelial ovarian cancer (EOC)
(including primary peritoneal and/or fallopian tube cancer), including
platinum-sensitive and platinum-resistant patients, and the proportion of
platinum-resistant patients was less than 40%
4. ≥2 previous lines of treatment
5. Patients must have received one prior PARP inhibitor therapy:
1. Prior PARP inhibitor for maintenance treatment: the duration of prior PARP
inhibitor exposure must have been ≥12 months following a first line of
chemotherapy or ≥6 months following a second or subsequent line of chemotherapy
2. Prior PARP inhibitor for treatment: the duration of prior PARP inhibitor
exposure must have been ≥4 months
6. Patients must have lesions that can be measured according to RECIST v1.1 criteria;
7. Life expectancy ≥16 weeks;
8. Eastern United States Cancer Collaboration Group (ECOG) score 0-1;
9. Pregnant women must agree to effective contraception ≥120 days during the study
period and after the last drug administration, and the results of serum pregnancy
tests were negative 7 days ≤ before the first drug administration;
10. Patients must have adequate organ function as indicated by the following laboratory
values:
1. Hemoglobin ≥ 9 g/dL
2. Absolute neutrophil count (ANC) ≥1.5 x 109/L
3. Platelets ≥ 80 x 109/L
4. Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN)
5. Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x ULN
6. Serum creatinine <1.5 x ULN
Exclusion Criteria:
1. Prior treatment with Pamiparib;
2. Patients who are candidates for surgery after disease progression;
3. Patients who have been treated with chemotherapy, biologic therapy, immunotherapy,
investigational agent, anti-cancer Chinese medicine, or anti-cancer herbal remedies
≤ 14 days (or ≤5 half-lives, whichever is shorter) prior to starting study drug, or
who have not adequately recovered from the side effects of such therapy;
4. Patients who have undergone major surgery/surgical therapy for any cause ≤ 4 weeks
prior to starting study drug. Patients must have adequately recovered from the
treatment and have a stable clinical condition before entering the study;
5. Patients who have undergone radiotherapy for any cause ≤ 14 days prior to starting
study drug. Patients must have adequately recovered from the previous treatment and
have a stable clinical condition before entering the study;
6. Untreated and/or active brain metastases; i. A scan to confirm the absence of brain
metastases is not required ii. Patients with treated brain metastases must be off
corticosteroids for ≥ 14 days and have no signs or symptoms of progressive brain
metastases
7. Inability to swallow oral medications (capsules and tablets) without chewing,
breaking, crushing, opening or otherwise altering the product formulation
8. Patients with any of the following cardiovascular criteria:
i. Cardiac chest pain, defined as moderate pain that limits instrumental activities
of daily living, ≤ 28 days prior to Day 1 ii. Evidence of symptomatic pulmonary
embolismwithin 4 weeks prior to Day 1 iii. Acute myocardial infarction ≤ 6 months
prior to Day 1 iv. Heart failure of New York Heart Association Classification III or
IV (see Appendix 12) ≤ 6 months prior to Day 1 v. ≥ Grade 2 ventricular arrhythmia ≤
6 months prior to Day 1 vi. Cerebrovascular accident ≤ 6 months prior to Day 1
9. Patients with other malignant cancer i. Except for surgically excised non-melanoma
skin cancer, adequately treated carcinoma in situ of the cervix, adequately treated
low-stage bladder cancer, ductal carcinoma in situ treated surgically with curative
intent, or a malignancy diagnosed ≥ 5 years ago with no current evidence of disease
and no therapy ≥ 5 years prior to Day 1
10. Diagnosis of myelodysplastic syndrome (MDS);
11. Known human immunodeficiency virus (HIV) infection, active viral hepatitis, or
active tuberculosis;
12. Use ≤ 10 days (or ≤ 5 half-lives, whichever is shorter), prior to Day 1, or
anticipated need for food or drugs known to be strong or moderate cytochrome P450
(CYP) 3A inhibitors or strong CYP3A inducers;
13. Pregnancy or nursing:
i. Females of childbearing potential require a negative serum pregnancy test ≤ 7
days before Day 1.
14. Known history of intolerance to the excipients of the pamiparib capsule;
15. Previous complete gastric resection, chronic diarrhea, active inflammatory
gastrointestinal disease, or any other disease-causing malabsorption syndrome.
i. Gastroesophageal reflux disease under treatment with proton pump inhibitors is
allowed.
16. Active bleeding disorder, including gastrointestinal bleeding, as evidenced by
hematemesis, significant hemoptysis, or melena ≤ 6 months before Day 1;
17. Any illness that investigator thinks makes the patient unsuitable for entry into the
study;
18. Unsolved acute effects of prior therapy of ≥ Grade 2 i. Except for AEs not
considered a likely safety risk (eg, alopecia, neuropathy, and specific laboratory
abnormalities)
Gender:
Female
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Zhejiang Cancer Hospital
Address:
City:
Hangzhou
Country:
China
Start date:
August 16, 2022
Completion date:
December 2024
Lead sponsor:
Agency:
Zhejiang Cancer Hospital
Agency class:
Other
Source:
Zhejiang Cancer Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05489926